Basel Medical Groupの空売り状況は、投資家がBasel Medical Groupの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Basel Medical Group (NASDAQ:BMGL) 株価情報, 空売り情報

Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.

Basel Medical Group Ltd - ordinary shares

Basel Medical Group Ltd

WIIM

DELL

Dell Technologies shares are trading lower amid reports indicating the Trump administration is widening its spending review beyond consulting firms to include tech companies.

REPL

Replimune Group shares are trading higher after the company provided updates for RP1 plus Nivolumab at ASCO 2025. Additionally, Piper Sandler raised its price target on the stock from $14 to $22.

INVX

Innovex International shares are trading higher after the company announced the acquisition of Citadel Casing Solutions.

Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) will release its first-quarter earnings results before the <a href="https://www.benzinga.com/quote/OLLI/earnings">opening bell on Tuesday, June 3.</a>
Analysts expect the Harrisburg, Pennsylvania-based company to report quarterly earnings at 71 cents per share, down from 73 cents per share in the year-ago period. Ollie&#8217;s Bargain Outlet projects to report quarterly revenue at $565.75 million, compared to $508.82 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 19, the company reported fourth-quarter adjusted earnings per share of $1.19, in line with the analyst consensus estimate. Quarterly sales of $667.1 million (up 2.8% year over year) missed the analyst consensus estimate of $674.5 million.
Ollie&#8217;s Bargain Outlet shares fell 0.3% to close at $111.45 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Keybanc analyst Bradley Thomas maintained an Overweight rating and increased the price target from $125 to $135 on May 20, 2025. This analyst has an accuracy rate of 77%.</li>
<li>JP Morgan analyst Matthew Boss maintained an Overweight rating and raised the price target from $135 to $137 on May 19, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Piper Sandler analyst Peter Keith maintained an Overweight rating and cut the price target from $126 to $124 on March 20, 2025. This analyst has an accuracy rate of 72%.</li>
<li>UBS analyst Mark Carden maintained a Neutral rating and raised the price target from $117 to $123 on March 20, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating and boosted the price target from $108 to $118 on March 20, 2025. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying OLLI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="633" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02044923/image-2-1024x633.png" alt="" class="wp-image-934779" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02044923/image-2-1024x633.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02044923/image-2-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02044923/image-2-768x474.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02044923/image-2.png 1096w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

OLLI

Ollie's Bargain Outlet Likely To Report Lower Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Monday.
The Dow traded down 0.49% to 42,064.07 while the NASDAQ rose 0.21% to 19,154.77. The S&amp;P 500 also fell, dropping, 0.11% to 5,905.30.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a>
Leading and Lagging Sectors Energy shares jumped by 0.6% on Monday.
In trading on Monday, real estate stocks fell by 1.5%.
Top Headline
The ISM manufacturing PMI declined to 48.5 in May compared to 48.7 in April, also missing market estimates of 49.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares shot up 486% to $28.90 after the company announced its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.</li>
<li>Shares of Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) got a boost, surging 64% to $31.12 after the company released ORIGIN Phase 3 trial data.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares were also up, gaining 51% to $10.34 after the company announced a 250MW AI data center lease with CoreWeave.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares dropped 20% to $6.01. The company provided updated data for the dose escalation part of its Phase 1/2 trial of GFH375.</li>
<li>Shares of SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) were down 37% to $48.35 after the company announced a mixed-shelf offering</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) was down, falling 32% to $0.73 after the company announced it commenced a public offering of pre-funded warrants.</li>
</ul>
Commodities In commodity news, oil traded up 3.3% to $62.82 while gold traded up 2.6% at $3,400.70.
Silver traded up 4.7% to $34.595 on Monday, while copper rose 3.6% to $4.8470.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 declined 0.14%, while Spain's IBEX 35 Index rose 0.36%. London's FTSE 100 rose 0.02%, Germany's DAX 40 fell 0.28% and France's CAC 40 fell 0.19% during the session.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei falling 1.30%, Hong Kong's Hang Seng Index dipping 0.57% and India's BSE Sensex declining 0.1%.
Economics
<ul class="wp-block-list">
<li>The ISM Manufacturing PMI declined to 48.5 in May compared to 48.7 in April, also missing market estimates of 49.5.</li>
<li>U.S. construction spending declined by 0.4% month-over-month to an annual rate of $2,152.4 billion in April following a revised 0.8% fall in March.</li>
<li>The S&amp;P Global manufacturing PMI was revised lower to a reading of 52 in May versus a preliminary reading of 52.3.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719355/top-3-utilities-stocks-that-may-crash-in-june">Top 3 Utilities Stocks That May Crash In June</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

APLD

LYRA

SBET

VERA

VSTM

Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May

Bank of America upgraded Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from &#8216;Neutral&#8217; to &#8216;Buy,&#8217; calling the jet maker a key beneficiary of President <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump&#8216;s trade talks</a>.
What Happened: "Boeing aircraft have emerged as the favored trade tool for&nbsp;the&nbsp;Trump&nbsp;Administration&nbsp;in&nbsp;recent trade deals," Bank of America analyst Ronald J. Epstein said in the note shared Monday.
"We suspect this will continue," he added.
Epstein also raised its price target to a Street-high $260 amid signs of <a href="https://www.benzinga.com/analyst-ratings/analyst-color">a long-awaited turnaround.</a>
The new price target implies a 25.4% upside from Boeing's last close at $207.32. 
Here are the latest developments that unfolded from Trump&#8217;s travels:
<ul class="wp-block-list">
<li>IAG, owner of British Airways and other European carriers, announced a nearly $13 billion purchase for 32 new Boeing aircraft.</li>
<li>Qatar Airways intends to buy up to 210 Boeing aircraft after Trump visited the Arabian Peninsula and agreed to accept a <a href="https://www.benzinga.com/25/05/45338985/trump-reportedly-set-to-accept-flying-palace-from-qatar-white-house-says-lavish-gift-of-boeing-jumbo-jet-complies-with-all-applicable-laws" target="_blank" rel="noreferrer noopener">Boeing 747</a> from Qatar as a gift.</li>
<li>Etihad Airways confirmed an order for 28 new Boeing long-haul aircraft during Trump&#8217;s visit to the United Arab Emirates.</li>
<li>And China <a href="https://www.benzinga.com/markets/25/04/44837703/chinas-ban-on-boeing-could-be-short-lived-but-trump-administration-cant-ignore-trade-fallout-warns-analyst">lifted its long-standing ba</a>n on Boeing jets, opening the door to more deliveries in a key growth market.</li>
</ul>
"These set a precedent for future global trade negotiations, to BA's benefit," Epstein said.
BofA doesn't see backlog alone driving valuation, but it highlights Boeing's new role as a trade facilitator. Combine that with operational improvements and asset sales, Epstein adds, it creates a "buying opportunity.&#8221; 
The F-47 Next Generation Air Dominance contract—awarded earlier this year—is also a win for Boeing's defense business. It secures a foothold in a decades-long fighter program and could help draw top engineering talent to the firm.
Why It Matters: Boeing is attempting to pull out of a crisis. A tough first quarter included a $2.9 billion accounting loss tied to high production costs. That translates to a loss of roughly $30 million per aircraft.
The company also remains under heightened scrutiny due to public concern over the safety of its aircraft. Various events, including mid-air malfunctions, engine fires, and two fatal 737 MAX plane crashes that claimed 346 lives, have significantly impacted its reputation.
Boeing also happens to have the backing of Trump&#8217;s Department of Justice, which recently moved to dismiss criminal <a href="https://www.benzinga.com/markets/equities/25/05/45689735/us-justice-department-seeks-to-dismiss-boeings-fraud-charges-on-737-max-crashes-that-killed-over-300">fraud charges against the company</a>.
It now claims to be restoring stability in its core 737 program.
Even so, Epstein said Boeing is on track to produce 38 jets per month by the fourth quarter. That's up from 25 in March and 33 in April. The company may even push to 42 jets per month by year-end if the Federal Aviation Administration lifts its current cap.
Epstein added that Boeing has reduced traveled work by 50% and continues to unwind excess inventory, especially 737-8 aircraft built for Chinese customers before 2023.
What&#8217;s Next: The analyst also expressed confidence in CEO Kelly Ortberg, appointed last August, calling him central to the company's restructuring. 
Ortberg helped negotiate an end to the 53-day IAM strike, launched portfolio realignments, and implemented new safety systems.
Under his leadership, Boeing is also shedding non-core assets—most notably, its planned $10.6 billion sale of Digital Aviation Solutions.
"Sisyphus [is]&nbsp;on the path to&nbsp;breaking&nbsp;the&nbsp;&#8216;doom loop&#8217;," Epstein said, using a Greek myth to describe Boeing's woes.
Looking ahead, BofA estimates earnings per share will jump from 35 cents this year to $6.40 by 2027. Free cash flow is forecast to swing from a $3.5 billion loss in 2025 to $5.5 billion in 2027. Further upside is tied to the 787 and MAX programs.
&#8220;A premium to the market fairly reflects the strong demand for commercial jets, impending production ramp, steady improving execution and the F-47 program,&#8221; Epstein said.
Read now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45724821/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">Trump&#8217;s Manufacturing Narrative Weakens As May Data Shows Sharper Contraction, Stubborn Inflation </a></li>
</ul>
Image: Shutterstock

Politics

Boeing Just Got A Major Stock Upgrade: It's Trump's 'Favored Trade Tool,' Says Bank Of America

NRIX

Nurix Therapeutics shares are trading higher after announcing Sanofi has exercised its option to exclusively license the company's STAT6 program and will receive licensing extension fees.

Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) has outperformed the market over the past 10 years by 6.09% on an annualized basis producing an average annual return of 17.04%. Currently, Sea has a market capitalization of $96.62 billion. 
Buying $1000 In SE: If an investor had bought $1000 of SE stock 10 years ago, it would be worth $4,825.84 today based on a price of $163.21 for SE at the time of writing.
<h3>Sea's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748882713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Sea 10 Years Ago Would Be Worth This Much Today

Legal

KEYS

Watching Keysight Technologies; Reuters Cites Court Filing Saying U.S. Files Antitrust Lawsuit To Block Keysight Technologies Purchase Of Spirent Communications; Proposes Requiring Divesting Of Some Assets Before Allowing Merger To Be Completed

Goldman Sachs analyst Jordan Alliger upgraded Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>)&nbsp;from Neutral to Buy and raised the price forecast <a target="_blank" href="https://www.benzinga.com/quote/SAIA/analyst-ratings" rel="noreferrer noopener">from&nbsp;$387&nbsp;to&nbsp;$410</a>.
The analyst believes that the company can continue to gain market share and grow its tonnage at a faster pace than overall industry trends.
Alliger cites regional cross-selling opportunities with current and new customers and potentially increased penetration of national accounts by offering a wider service area through its recent network expansion as growth catalysts.
Further, increased Less-Than-Truckload (LTL) volume growth should lead to better capacity utilization, which in turn reduces cost per shipment and significantly accelerates margins, adds the analyst.
Meanwhile, the analyst notes that the company faces a challenge in achieving the necessary density to offset terminal expansion costs amid a freight recession.
This, combined with persistent weakness in legacy SAIA volumes due to soft LTL industry fundamentals, has recently resulted in margin underperformance, adds the analyst.
Alliger says that this situation could lead to additional quarterly EPS volatility until industry volumes improve, which would enhance network productivity and efficiency.
The analyst believes that this will put SAIA back on a path toward significant incremental margin opportunities and above-average long-term industry EPS growth rates despite possible near-term margin pressure.
Overall, Alliger thinks that it is feasible for SAIA to move into the low-80% operating ratio (OR) range and eventually below 80%, compared to an OR of over 90% prior to COVID-19 and in the first quarter of 2025.
Price Action: SAIA shares are down 1.5% at $260.22 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/44954335" target="_blank" rel="noreferrer noopener">Old Dominion Earnings Shine Despite Revenue Slide, CEO Blames &#8216;Ongoing Softness&#8217; In Economy</a></li>
</ul>
Photo: Shutterstock

Upgrades

SAIA

Goldman Turns Bullish On Saia, Sees Room For Shipping Efficiency, Profit Growth

Grupo Cibest shares are trading higher after UBS raised its price target on the stock from $35 to $38.

Verastem Oncology&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) released on Monday updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">VS-7375 in the U.S.)</a>.
As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall response rate (ORR) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45721800/verastem-oncology-announces-updated-data-from-partner-genfleet-therapeutics-phase-1-study-in-china" rel="noreferrer noopener">of 52% and 42%, respectively</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45297255/fda-grants-accelerated-approval-to-verastems-combination-drug-for-ovarian-cancer" rel="noreferrer noopener">FDA Grants Accelerated Approval To Verastem&#8217;s Combination Drug For Ovarian Cancer</a>
Verastem&#8217;s partner, GenFleet Therapeutics, presented the updated data at the 2025 American Society of Clinical Oncology Annual Meeting.
ASCO 2025 Presentation Highlights
<ul class="wp-block-list">
<li>GenFleet reported that 62 patients were enrolled in the Phase 1 portion of the study in China, receiving oral doses ranging from 100 to 900 mg daily.</li>
<li>As of the data cutoff of May 16, 2025, 23 efficacy-evaluable patients with PDAC and 12 efficacy-evaluable patients with NSCLC, who received daily dosages of 400 or 600 mg and had at least one post-treatment tumor assessment, achieved an ORR of 52% and a disease control rate (DCR) of 100%, and an ORR of 42% and a DCR of 83%, respectively.</li>
</ul>
As of the cutoff date of March 31, 2025, GenFleet reported that no dose-limiting toxicities (DLTs) were observed across all dose levels (100-900 mg QD), and the treatment-related adverse events (TRAEs) were mostly Grade 1/2.
VSTM Price Action: Verastem Oncology stock is trading 18.62% lower at $6.12 at publication on Monday.
<h1 class="wp-block-heading">Looking At Trends: Verastem Oncology</h1>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Verastem, an investor could make an assessment about a stock's long-term prospects using a moving average and trend line. 
If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Verastem, the 200-day moving average sits at $4.96, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is below the current price of $6.13. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45724879/cactus-takes-majority-stake-in-baker-hughes-spc-for-global-reach" target="_blank" rel="noreferrer noopener">Cactus Takes Majority Stake In Baker Hughes&#8217; SPC For Global Reach</a></li>
</ul>
Photo: Shutterstock

Health Care

Movers

What's Going On With Verastem Oncology Stock On Monday?

ARVN

ARVN stock has given up its prior loss. Arvinas shares were trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $10 to $9.

When you request an AI model to create a social media post or generate a Picasso-inspired animal graphic, there's a small but quantifiable energy cost associated with it, accompanied by emissions released into the atmosphere. While each individual query typically consumes less energy than briefly using a deep fryer, the effect might seem negligible. However, as more people rely on AI tools, these cumulative impacts become increasingly significant. According to Morgan Stanley, power demand from generative AI will <a href="https://www.morganstanley.com/ideas/ai-energy-demand-infrastructure">increase at an annual average of 70%</a> through 2027, mostly from the growth of AI-dependent data centers.&nbsp;
AI's growing dependency on energy-intensive processes is not only reshaping infrastructure at an unprecedented scale but also challenging the global push toward sustainability. As AI systems become more pervasive, their energy consumption is accelerating, and with it, questions about the long-term implications for the environment, energy resources, and technology itself. From data centers to inference models, the power demands of AI are poised to grow exponentially in the coming years and experts are taking note.&nbsp;
Some of AI's best minds gathered in Cambridge, Massachusetts, May 5-7, 2025, at the <a href="https://event.technologyreview.com/emtech-ai-2025/home">EmTech AI Conference</a>, to discuss the sustainability implications of artificial intelligence. Editorial members of the esteemed <a href="https://www.technologyreview.com/">MIT Technology Review</a> publication explored the scope of AI's energy impact, where it's heading, and why it's imperative that decisions made today balance innovation with responsibility. Ultimately, these experts warn that we are at a critical juncture that will determine whether future AI innovations can coexist with global efforts to combat climate change.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="560" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140240/EmTech2-1024x560.png" alt="MIT Technology Review from left to right: Will Douglas Heaven, Sr. Editor; James O'Donnell, AI Reporter; Mat Honan, Editor in Chief" class="wp-image-13720" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140240/EmTech2-1024x560.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140240/EmTech2-300x164.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140240/EmTech2-768x420.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140240/EmTech2.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
MIT Technology Review from left to right: Will Douglas Heaven, Sr. Editor; James O'Donnell, AI Reporter; Mat Honan, Editor in Chief 
<h2 class="wp-block-heading">The Growing Energy Demands of AI</h2>
AI's energy usage comes from two primary operations: training models and inference tasks. Training complex AI models, such as large language models and image generation systems like ChatGPT, Gemini, Llama, and Claude, require massive computational power and energy resources. Training processes for advanced models can require weeks or even months of operating fleets of high-performance GPUs, processing vast datasets. The carbon costs of this process are significant, and they represent only part of the challenge.
Inference, the step in which AI models respond to user inputs or requests (e.g., generating text, answering search queries, or creating art), is set to consume an even greater share of energy in the near future. Unlike training, inference happens on-demand and at scale. Every interaction with an AI system, whether a personal assistant like ChatGPT or a visual design tool, requires computing resources, creating a cumulative energy burden as these interactions multiply.
"We're moving to this world where multiple AI models are answering billions of queries daily, and those inferences are already a massive and growing energy hog," explained Mat Honan, MIT Technology Review's editor in chief. "And if we want to keep up with the expected demand, we're going to need a lot more power than we currently have."
The magnitude of this shift cannot be understated: as AI tools become more integrated into consumer and enterprise systems, the energy used to power these tools will continue to grow, raising complex questions about how much power our infrastructure can handle and its implications for the environment. So, where will this power come from?
<h2 class="wp-block-heading">Just How Much Energy Do We Need?</h2>
Establishing just how much energy will be required to meet future AI demands is tricky. Experts are merely speculating.&nbsp;
"I can't emphasize enough, we truly don't know anything about how much energy is used up when you ask a query or generate a video," MIT Technology Review AI Reporter, James O'Donnell said. "We make estimates about how much energy is used specifically in inferencing, and there's all sorts of ways that you can do that, but it's all very indirect."&nbsp;
And that's at the functional level, at the data center level it's still being figured out what energy sources are going to power this AI revolution.
<h2 class="wp-block-heading">The Role of Data Centers: Feeding AI's Energy Hunger</h2>
Data centers serve as the backbone of AI systems. These sprawling facilities house the servers and processors that enable AI models to function. However, their scale, complexity, and energy consumption are raising alarms globally.&nbsp;
Take Nevada, for example, where tech giants like Google and Apple have built vast data centers in what is already one of America's driest states. These facilities consume massive amounts of energy to keep high-performance servers operating at optimum temperatures. Cooling technologies are vital in these desert locations, requiring significant water use and power to sustain the operations. Nearly half of the energy demands of a data center comes from the need to cool it.&nbsp;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="509" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140339/Apple-NV-1024x509.png" alt="" class="wp-image-13721" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140339/Apple-NV-1024x509.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140339/Apple-NV-300x149.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140339/Apple-NV-768x381.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140339/Apple-NV.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Apple solar data center, Nevada 
The problem isn't limited to Nevada. In Louisiana, Meta is constructing its largest-ever data center, a project geared to support its AI ambitions. However, this venture relies heavily on power from natural gas plants, undermining clean energy goals. Such developments reveal troubling contradictions: while companies acknowledge the importance of sustainability, they remain tied to energy sources that perpetuate dependence on fossil fuels. "Renewables, for the most part, lack the kind of consistency a data center requires," Honan pointed out.&nbsp;
A surge in AI-driven electricity demand also places additional pressure on power grids, inadvertently accelerating the buildout of natural gas-based energy facilities. This reliance on fossil fuels, driven in part by AI's electricity needs, presents a serious challenge to climate objectives, as industries struggle to scale renewable solutions quickly enough to meet demand.
<h2 class="wp-block-heading">Can Nuclear Power Solve AI's Energy Crisis?&nbsp;&nbsp;</h2>
To meet the mounting energy demand posed by AI, many are turning to nuclear power as a potential solution. Viewed as a cleaner alternative to fossil fuels, nuclear energy offers a steady, reliable source of electricity that could, in theory, power future AI operations sustainably. However, there are significant barriers to this transition. "While nuclear may sound great, it takes years, sometimes a decade or more to bring a new plant online," Honan remarked.&nbsp;
Additionally, policy hurdles, public resistance, and high costs further complicate nuclear adoption. As a result, it may be years—if not decades—before nuclear energy can meaningfully contribute to fueling AI's growth at scale. While the idea holds promise, it is far from an immediate solution to AI's energy dilemma.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="780" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA-1024x780.png" alt="Source: Nuclear Innovation Alliance 
" class="wp-image-13722" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA-1024x780.png 1024w, <a href="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA-300x229.png" title="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA-300x229.png">https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA-300x229.png</a> 300w, <a href="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA-768x585.png" title="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA-768x585.png">https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA-768x585.png</a> 768w, <a href="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA.png" title="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA.png">https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140416/NIA.png</a> 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Source: Nuclear Innovation Alliance
Companies are investing heavily in exploring nuclear options as part of their long-term plans to decarbonize data infrastructure, particularly overseas. China's first nuclear power plant was connected to the grid in 1991, and within a few decades, it has developed the <a href="https://www.technologyreview.com/2025/01/14/1109963/whats-next-for-nuclear-power/">third-largest nuclear fleet globally</a>, behind only France and the United States. This year, China is expected to bring four large reactors online, with several more planned for commissioning in 2026.
<h2 class="wp-block-heading">Why AI's Energy Problem Matters</h2>
At present, AI's energy footprint constitutes a relatively small portion of global electricity use. However, its trajectory is concerning. Analysts warn that if unchecked, AI's growing power consumption could have a cascading effect on broader electrification plans and efforts to combat climate change. The energy requirements of data centers represent a microcosm of the broader electrification challenges humanity faces: as society adopts new technologies reliant on electricity, ensuring sustainable energy practices becomes increasingly critical.
Moreover, AI's energy needs expose existing inequities in resource allocation. Communities hosting energy-intensive data centers may bear disproportionate environmental impacts, from water shortages to higher emissions associated with local power generation. This creates a moral imperative for policymakers and corporations to adopt equitable, sustainable strategies.
<h2 class="wp-block-heading">The Case for Optimism: Toward Energy-Efficient AI&nbsp;&nbsp;</h2>
Despite these challenges, there are reasons to feel optimistic about AI's energy future. Emerging technologies and innovations could significantly reduce the energy intensity of AI systems in years to come. Improvements in software and hardware, including the development of more efficient processors, are already underway.&nbsp;
"On the software side, there's always going to be efficiencies made in the way AI models themselves are made," MIT Technology Review Senior Editor, Will Douglas Heaven, said. "We can be smarter about training with more curated, specialized data where you don't need to throw everything in it and then run models for weeks and weeks on it."
Companies can also adopt better monitoring and reporting practices to enhance accountability. Transparent reporting on AI's energy use, coupled with clear targets for reducing environmental impact, could represent a critical step toward aligning technological innovation with climate goals. Renewable energy investments and technologies like liquid cooling are further reasons for cautious optimism, as they could minimize the environmental strain of data centers.
Lastly, the increasing emphasis on sustainable infrastructure aligns AI innovation with global electrification policies. Governments and the private sector alike are exploring pathways to design AI systems that contribute to renewable energy networks rather than strain them. The future of AI in renewable energy is incredibly promising, <a href="https://www.aon.com/en/insights/articles/ai-innovations-in-renewable-energy-transforming-the-sector">according to AON</a>, with numerous advancements and applications that are set to revolutionize the sector.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="381" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140502/AON-1024x381.png" alt="" class="wp-image-13723" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140502/AON-1024x381.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140502/AON-300x112.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140502/AON-768x286.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02140502/AON.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Source: AON Website&nbsp; 
<h2 class="wp-block-heading">Looking Forward&nbsp;</h2>
AI holds the potential to transform society in unprecedented ways. Yet, its rapid growth is a double-edged sword. The power-hungry nature of AI systems presents a litmus test for humanity's ability to manage technological progress responsibly while safeguarding our planet.
As the energy demands of AI mount, urgent steps must be taken to align innovation with sustainability. Solutions such as energy-efficient systems, equitable infrastructure planning, and investments in renewable energy are critical to mitigating AI's environmental impact. Importantly, collaboration between industry leaders, governments, and scientists will be essential to ensuring that AI's immense potential benefits humanity without undermining our shared future.
The coming years will define not just the trajectory of AI but also the legacy of our response to the challenges it poses on our planet. By addressing AI's energy consumption today, we can ensure that the technology powering the future is as sustainable as it is transformative.
Feature image compliments of MIT EmTech

Opinion

General

Tomorrow's Energy Crisis? MIT's Alarming Analysis of AI Power Consumption

Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) (the "Company"), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the form of a stock bonus. Each shareholder of the Company of record at the close of business on June 12, 2025 will receive 37 additional shares for every share held on the record date. The Company expects the additional shares will be distributed on June 13, 2025. Subject to the final approval by the Nasdaq Capital Market, trading is expected to begin on a post-stock split adjusted basis at market open on June 16, 2025.
The forward stock split is intended to enhance liquidity in the market for the Company's ordinary shares and make the shares more accessible to investors.
Following the split, the Company's outstanding shares will be increased at the ratio of the forward stock split. The Company's authorized share capital and the share par value will remain unchanged.
There will be no change to the Company's name, CUSIP or its current trading symbol in connection with the forward stock split.
No action is required by shareholders in connection with the forward stock split. Shareholders who hold their shares through a brokerage account will have their shares automatically adjusted to reflect the forward stock split. Registered shareholders will receive their additional shares through the Company's transfer agent.

Stock Split

Reported Earlier: Regencell Bioscience Announces 38-For-1 Forward Stock Split, With Share Distribution On June 13, 2025 And Post-Split Trading Set For June 16, 2025

BURU

Nuburu shares are trading lower after the company announced it will raise capital through a $100 million equity facility.

IBRX

ImmunityBio shares are trading higher after the company announced it received FDA extended access authorization for the treatment of lymphopenia with ANKTIVA.

Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile
Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology
For U.S. media and investors only&nbsp;
DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial evaluating Ziihera&#xAE; (zanidatamab-hrii), a dual HER2-targeted bispecific antibody, in combination with chemotherapy for the investigational use in first-line HER2-positive (IHC 3+ or IHC 2+/FISH+) locally advanced nonresectable gastroesophageal adenocarcinoma (mGEA). The data were featured as a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439717-1&amp;h=49472503&amp;u=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045(25)00287-6%2Ffulltext&amp;a=The+Lancet+Oncology">The Lancet Oncology</a>.
Among 41 patients with centrally confirmed HER2-positive tumors, treatment with Ziihera in combination with physician's choice of chemotherapy resulted in a median progression-free survival (PFS) of 15.2 months [95% CI: 9.5, 33.4], and a median overall survival (OS) of 36.5 months [95% CI: 23.6, not estimable (NE)]. Median PFS remained stable with the additional four-year follow-up, consistent with previously reported results.
Among all 46 patients in the study with HER2-expressing mGEA, median PFS was 12.5 months [95% CI: 8.2, 21.8], and median OS also reached 36.5 months [95% CI: 23.6, NE], with the longest observed survival at 57.9 months (censored at data cutoff). Long-term follow-up also demonstrated low discontinuation rates, with no new safety signals observed.

Biotech

JAZZ

Jazz Pharmaceuticals Reports Long-Term Phase 2 Data For Ziihera Showing 36.5-Month Median Overall Survival And Durable Responses In HER2-Positive Gastroesophageal Cancer, With Manageable Safety Profile; Results Presented At ASCO 2025 And Published In The Lancet Oncology

ALLO

Allogene Therapeutics shares are trading higher after the company provided updates for its Phase 1 TRAVERSE study of ALLO-316.

CLEU

CLEU stock has given up its prior loss. China Liberal Education shares were trading lower after the company announced it will be suspended from Nasdaq for failing to address a 20-F delinquency filing.

Press Releases

Basel Medical Group Ltd Prices US$8,820,000 Initial Public Offering

Basel Medical Group Ltd Announces Closing of US$8,820,000 Initial Public Offering

Basel Medical Group Ltd Announces Exercise of Overallotment Option

Basel Medical Group Signs Agreement to Acquire Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia

Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia

Basel Medical Group Ltd Kicks Off US$ 1.0 Billion Bitcoin (BTC) Acquisition Strategy Move

Basel Medical Group Subsidiary Awarded S$375 Million Contract to Supply Healthcare Products; Group to Enhance AI-Powered Healthcare Supply Chain Capabilities

Basel Medical Group Ltd Enters into US$ 1.0 Billion Bitcoin (BTC) Purchase Agreement

Basel Medical Group Ltd Reaffirms Strong Financial Position Amid Market Volatility

The CHIPS Act and Peraso Inc. (NASDAQ: PRSO): Advancing Semiconductor Innovation and National Security – More Stocks Inside

BLRX

BMGL

BSLK

PRSO

SNYR

TIRX

VIVK

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Basel Medical Group

空売り

Basel Medical Group (NASDAQ:BMGL) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル